Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Iowa Nilotinib Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.05.74

    Cavhanza and Danziten (nilotinib) Coverage Criteria

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.05.74 alerts

    Get alerted when Policy 05.05.74 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity criteria for Cavhanza and Danziten (nilotinib) in adult members with Philadelphia chromosome-positive chronic myeloid leukemia.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyCavhanza and Danziten (nilotinib) Coverage Criteria
    Policy CodePolicy 05.05.74
    Change TypeNo material change
    Effective DateSep 21, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit Philadelphia chromosome or BCR::ABL confirmation and, when applicable, BCR::ABL1 mutation results with the prior authorization request.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2FDA-approved CML indication categories
    7 monthsInitial authorization period
    12 monthsContinuation authorization period
    112 tablets/28 daysQuantity limit per tablet strength

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    BCR::ABL1 ≤10%
    Continuation response threshold

    Coverage Criteria

    Initial Therapy — Chronic Myeloid Leukemia

    Authorization may be granted when CML is confirmed by cytogenetic and/or molecular detection of the Philadelphia chromosome or BCR::ABL gene and ANY one of the following criteria is met.

    CML confirmation and one qualifying treatment-history pathway

    • Qualifying treatment-history pathway

      • The member has not received prior therapy with a TKI, such as bosutinib, dasatinib, imatinib, or ponatinib.
      • The member experienced toxicity or intolerance to prior therapy with a TKI.
      • The member experienced resistance to prior therapy with a TKI and BCR::ABL1 mutational testing is negative for all of the following: T315I, Y253H, E255K/V, and F359V/C/I.Negative for all of T315I, Y253H, E255K/V, and F359V/C/I

        Mutation testing is required where applicable.

    Continuation Therapy — Chronic Myeloid Leukemia

    Authorization may be granted for continued treatment when ALL continuation criteria are met.

    Continuation therapy requirements

    • BCR::ABL1 is less than or equal to 10%.≤10%
    • There is no evidence of disease progression.
    • There is no unacceptable toxicity while the member is receiving the current regimen for 6 months or greater.Current regimen ≥6 months

    Members who do not meet the initial-approval or continuation-approval criteria are excluded from medically necessary coverage. Members receiving the requested medication through samples or a manufacturer patient assistance program must still meet the initial-approval criteria.

    Cavhanza and Danziten (nilotinib) are considered not medically necessary when the member does not meet the criteria set forth in this policy.

    Initial Therapy Criteria

    CML Initial Therapy

    Authorization may be granted for treatment of CML confirmed by Philadelphia chromosome or BCR::ABL detection when ANY one qualifying treatment-history pathway is met.

    Initial therapy requirements

    • Qualifying treatment-history pathway

      • The member has not received prior therapy with a TKI, including bosutinib, dasatinib, imatinib, or ponatinib.
      • The member experienced toxicity or intolerance to prior therapy with a TKI.
      • The member experienced resistance to prior therapy with a TKI and BCR::ABL1 mutation testing is negative for T315I, Y253H, E255K/V, and F359V/C/I.Negative for all listed mutations

        Mutation testing is required where applicable.

    Continuation Therapy Criteria

    CML Continuation Therapy

    Authorization may be granted for continued treatment of CML when all listed conditions are met.

    Continuation therapy

    • BCR::ABL1 response: BCR::ABL1 is less than or equal to 10%.≤10%
    • No disease progression: There is no evidence of disease progression.
    • No unacceptable toxicity and adequate duration: There is no unacceptable toxicity while on the current regimen for 6 months or greater.≥6 months

    Authorization and Documentation Requirements

    Prior Authorization

    CML Prior Authorization Required

    Prior authorization is required for Cavhanza or Danziten (nilotinib) to treat chronic myeloid leukemia (CML). Authorization may be granted when the member has no prior TKI therapy, has experienced TKI toxicity or intolerance, or has experienced TKI resistance with the required negative mutation testing.

    • Document the member’s prior TKI treatment history, including any toxicity, intolerance, or resistance.
    • For resistance to prior TKI therapy, submit the applicable BCR::ABL1 mutation testing results.
    Documentation Required

    Submit CML Confirmation

    For CML treatment, submit cytogenetic and/or molecular testing confirming detection of the Philadelphia (Ph) chromosome or the BCR::ABL gene.

    • Required documentation: results of cytogenetic and/or molecular testing for detection of the Ph chromosome or BCR::ABL gene.

    Policy Background

    Cavhanza and Danziten are nilotinib products used to treat adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Covered disease settings include newly diagnosed CML in the chronic phase and chronic- or accelerated-phase Ph+ CML that is resistant or intolerant to prior therapy including imatinib.

    Clinical Definitions

    Philadelphia chromosome-positive CML (Ph+ CML)
    ConditionPhiladelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)
    Defining findingPresence of the Philadelphia chromosome
    Molecular findingDetection of the BCR::ABL gene
    Chronic phase
    Disease phaseChronic phase CML
    Newly diagnosed contextEligible for adults with newly diagnosed Ph+ CML in chronic phase
    Prior-therapy contextEligible when Ph+ CML is resistant or intolerant to prior therapy that included imatinib

    Quantity Limits by Product and Strength

    Cavhanza 60 mg tablets
    ProductCavhanza 60 mg tablets
    Standard limit112 tablets
    Limit intervalPer 28 days
    Cavhanza 80 mg tablets
    ProductCavhanza 80 mg tablets
    Standard limit112 tablets
    Limit intervalPer 28 days
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyCavhanza and Danziten (nilotinib) Coverage Criteria
    Policy CodePolicy 05.05.74
    Change TypeNo material change
    Effective DateSep 21, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit Philadelphia chromosome or BCR::ABL confirmation and, when applicable, BCR::ABL1 mutation results with the prior authorization request.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation Therapy CriteriaAuthorization and Documentation RequirementsPolicy BackgroundClinical DefinitionsQuantity Limits by Product and Strength
    Documentation Required

    Mutation Testing After TKI Resistance

    When therapy is requested after resistance to prior TKI therapy, submit BCR::ABL1 mutation testing results. Authorization for this pathway requires negative results for all specified mutations.

    • Test for T315I, Y253H, E255K/V, and F359V/C/I, where applicable.
    • Submit the mutation testing results with the prior authorization request.
    Denial Risk

    Criteria Not Met

    Cavhanza and Danziten (nilotinib) are considered not medically necessary when the member does not meet the policy criteria. Members receiving the medication as samples or through the manufacturer’s patient assistance program must still meet the criteria for initial approval.

    • Requests that do not satisfy the applicable CML criteria may be denied.
    • Initial approval criteria apply regardless of access through samples or a manufacturer patient assistance program.
    Note

    Benefit Exclusions and Contract Limitations

    Benefit determinations are based on the applicable contract language in effect when services are rendered. Coverage is subject to applicable benefit exclusions, limitations, and exceptions, and benefits may vary by contract; individual member benefits must be verified.

    • Medical necessity is determined only when the benefit exists and no contract exclusion applies.
    • This medical policy may not apply to the Federal Employee Program; FEP benefits are determined by the Federal Employee Program.
    Accelerated phase
    Disease phaseAccelerated phase Ph+ CML
    Treatment contextEligible when the disease is resistant or intolerant to prior therapy that included imatinib
    Covered disease phases with prior therapyThe policy also identifies chronic-phase Ph+ CML in the same resistant or intolerant treatment context
    Danziten 71 mg tablets
    ProductDanziten 71 mg tablets
    Standard limit112 tablets
    Limit intervalPer 28 days
    Danziten 95 mg tablets
    ProductDanziten 95 mg tablets
    Standard limit112 tablets
    Limit intervalPer 28 days